A Primer on Interstitial Lung Disease and Thoracic Radiation.
Clinical decision making
Interstitial lung disease
Thoracic radiation
Toxicity
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
23
10
2019
revised:
05
02
2020
accepted:
11
02
2020
pubmed:
28
2
2020
medline:
7
1
2021
entrez:
28
2
2020
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.
Identifiants
pubmed: 32105810
pii: S1556-0864(20)30127-1
doi: 10.1016/j.jtho.2020.02.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
902-913Informations de copyright
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.